榛花消肾安胶囊对糖尿病肾病患者血清C-反应蛋白、肿瘤坏死因子-α和尿单核细胞趋化蛋白-1的影响  

Influence of Zhenghua Xiaoshen'an Capsules on Serum hs-CRP,TNF-alpha and Urine MCP-1 in Patients with Diabetic Nephropathy

作　　者：姜甫昇 南征 崔振海[3] 

机构地区：[1]长春中医药大学,吉林长春130000 [2]吉林省中医院内分泌科,吉林长春130021 [3]长春中医药大学附属医院骨伤康复科,吉林长春130000

出　　处：《辽宁中医杂志》2017年第6期1181-1183,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：吉林省科技发展计划项目(20150204090SF)

摘　　要：目的:榛花消肾安胶囊对糖尿病肾病患者血清C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和尿单核细胞趋化蛋白-1(MCP-1)水平的影响。方法:将2014年5月—2016年5月本院收治的96例糖尿病肾病患者按其临床治疗方法分成A组、B组和C组,每组32例,A组患者予降糖、控制饮食、降低氧化应激等常规基础治疗上予以西药缬沙坦胶囊口服治疗,B组患者在常规治疗基础上予以中成药榛花消肾安胶囊口服治疗,C组患者在B组基础上联合加用西药缬沙坦胶囊口服治疗,比较3组患者的临床疗效及临床炎症相关指标水平的变化。结果:(1)3组患者治疗前其CRP、IL-6、TNF-α和尿MCP-1水平均无明显差异(P>0.05),治疗后3组患者CRP、IL-6、TNF-α和尿MCP-1水平较治疗前均降低,且B组和C组降低程度较A组明显,C组较B组降低更甚,比较间均具有统计学意义(P<0.05);(2)治疗结束后,B组(81.25%)和C组临床总有效率(93.02%)明显高于A组(62.50%),且C组(96.88%)与B组(81.25%)临床总有效率比较具有统计学意义(P<0.05);(3)3组间不良反应发生率比较无统计学意义(P>0.05),且无明显严重不良反应事件发生。结论:榛花消肾安胶囊可明显降低DN患者血清hs-CRP、TNF-α和尿MCP-1水平,具有良好的临床疗效及安全性。Objective：To investigate the influence of Zhenghua Xiaoshen＇an Capsules on serum hs -CRP, TNF-α and urine MCP - 1 in patients with diabetic nephropathy. Methods ： A total of 96 cases with diabetic nephropathy in our hospital from May 2014 to May 2016 were selected and divided into group A,group B and group C,32 cases in each group. Group A patients were given Valsartan Capsules orally and routine treatment including hypoglycemic, controlling diet and reducing oxidative stress, Group B patients were given Zhenghua Xiaoshen＇an Capsules based on routine treatment. Group C patients were given Zhenghua Xiaosh- en＇an Capsules combined with Valsartan Capsules based on routine treatment. The clinical efficacy and levels of inflammation re- lated indicators were evaluated and compared among three groups. Results ： （ 1 ） The levels of CRP, IL - 6, TNF - α and urinary MCP - 1 were not significantly different among 3 groups before treatment （ P 〉 0. 05 ）. The levels of CRP, IL - 6, TNF - α and uri- nary MCP - 1 after treatment decreased significantly compared with those before treatment in 3 groups, and those in the B group and C group were more decreased significantly than those in A group and in C group decreased more significantly compared with those in the B group （P 〈0. 05）. （2） The clinical total effective rate of B group （81.25%） and C group （93.02%） were sig- nificantly higher than that in A group （62.50%） at the end of treatment, and those in group C （96.88%） were significantly higher than that in B group （ 81.25% ） （ P 〈 0. 05 ）. （3） The incidence of adverse reactions among 3 groups was not statistically significant （P 〉 0. 05） and no serious adverse events happened. Conclusion：Zhenghua Xiaoshen＇an Capsules can significantly re- duce the levels of serum hs - CRP,TNF - α and urine MCP - 1 in patients with DN and has good clinical efficacy and safety.

关 键 词：榛花消肾安胶囊 糖尿病肾病 C-反应蛋白 肿瘤坏死因子-Α 尿单核细胞趋化蛋白-1 

分 类 号：R587.2[医药卫生—内分泌]